


## SB273005

<b>Cat. No.:</b>	B6003
<b>CAS No.:</b>	205678-31-5
<b>Formula:</b>	C <sub>22</sub> H <sub>24</sub> F <sub>3</sub> N <sub>3</sub> O <sub>4</sub>
<b>M.Wt:</b>	451.44
<b>Synonyms:</b>	
<b>Target:</b>	Angiogenesis
<b>Pathway:</b>	Integrin
<b>Storage:</b>	Store at -20°C



## Solvent & Solubility

Soluble in DMSO

In Vitro

Preparing Stock Solutions	Solvent Concentration	Mass		
		1mg	5mg	10mg
	1 mM	2.2151 mL	11.0757 mL	22.1513 mL
	5 mM	0.4430 mL	2.2151 mL	4.4303 mL
	10 mM	0.2215 mL	1.1076 mL	2.2151 mL

Please refer to the solubility information to select the appropriate solvent.

## Biological Activity

Shortsummary

 $\alpha$  v $\beta$ 3 antagonist

 IC<sub>50</sub> & Target

In Vitro

### Cell Viability Assay

Cell Line:	MDA-MB-231 breast adenocarcinoma cell
Preparation method:	Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	1 $\mu$ mol/l
Applications:	In blood containing MDA-MB-231 cells, a combination of SB273005 and lamifiban inhibited tumor cell adhesion to vascular extracellular matrix (ECM).

In Vivo	<b>Animal experiment</b>	
	Animal models:	Male Lewis rats with adjuvant-induced arthritis
	Dosage form:	Oral administration, 10, 30, and 60 mg/kg, twice per day
	Applications:	In rat with adjuvant-induced arthritis, SB273005 (30 mg/kg, 60 mg/kg, p.o.) significantly reduced the symptoms of adjuvant-induced arthritis. When administered prophylactically to AIA rats, SB 273005 (twice per day) inhibited paw edema at doses of 10, 30, and 60 mg/kg, by 40%, 50%, and 52%, respectively.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1]. Gomes N, Vassy J, Lebos C, et al. Breast adenocarcinoma cell adhesion to the vascular subendothelium in whole blood and under flow conditions: Effects of  $\alpha v \beta 3$  and  $\alpha IIb \beta 3$  antagonists[J]. Clinical and Experimental Metastasis, 2004, 21(6): 553-561. [2]. Badger A M, Blake S, Kapadia R, et al. Disease - modifying activity of SB 273005, an orally active, nonpeptide  $\alpha v \beta 3$  (vitronectin receptor) antagonist, in rat adjuvant - induced arthritis[J]. Arthritis & Rheumatology, 2001, 44(1): 128-137.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.



[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)